Printer Friendly

WEX MEDICAL INSTRUMENTATION CO. LTD. ANNOUNCES LETTER OF INTENT

 VANCOUVER, British Columbia, Sept. 13 /PRNewswire/ -- Wex Medical Instrumentation Co. Ltd., a wholly owned subsidiary of Wex Technologies Inc., has signed a letter of intent with Dr. Zeng Zhi Ming of Henan, China, acquiring the worldwide rights to a drug that has shown encouraging results in the treatment of hepatocarcinoma (liver cancer) and leukemia. Wex will provide the funding necessary to complete the application for a manufacturing and marketing license with the relevant Chinese government agencies. Upon the grant of these licenses Dr. Zeng will transfer all rights, patents etc. to Wex. Compensation and royalty details will be announced when final agreements have been signed.
 Formula 168 has been tested in laboratories and clinics in China for over 10 years. Possessing characteristics that promote blood circulation by removing blood stasis, softening and absorbing masses, nourishing the blood and invigorating Qi (hormonal balance), Formula 168 has the dual effects of depressing tumor cell activities and increasing and stimulating the immunosystem of the body. In vivo, Formula 168 showed effectiveness in depressing the growth of neoplastic cells and improving the length of survival of mice with Lewis Lung Cancer, ECA ascitic cancers, L7712 leukemia and S(37) Sarcoma; in vitro, the results showed clear effects of killing neoplastic cells and depressing their growth in the laboratories of the Shanghai Institute of Pharmaceutical Industry and the Pharmacological Institute of Academy of Medical Sciences in Henan, China. In recent years, more than 100 patients with hepatocarcinoma have been treated with Formula 168 and have shown positive results. Clinically, most of the cases were late stage hepatocarcinoma. A number of leukemia patients who were unable to continue other treatment programs because of low whole blood counts and volume or bone marrow-suppression caused by the toxicity of chemotherapy, showed total or partial recovery within a relatively short time without side effects.
 Wex has also entered negotiations with Dr. Wang Jun Jian, professor at Huazhong University of Science and Technology, chairman of the Department of Biological Engineering and Professor at the Wuhan Institute of Botany, in regards to the worldwide rights to his process for the synthetic production of a taxol analog.
 -0- 9/13/93
 /CONTACT: Manfred Kurschner, 604-273-8081/
 (WEXTF)


CO: Wex Medical Instrumentation Co. Ltd. ST: British Columbia IN: MTC SU:

EH -- LA017 -- 1293 09/13/93 12:08 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 13, 1993
Words:385
Previous Article:COMPTROLLER OF THE CURRENCY TO CHAMPION EXPANSION OF COMMERCIAL BANK ACTIVITIES
Next Article:HUGHES AIRCRAFT WILL KEEP HEADQUARTERS IN CALIFORNIA
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters